Results 41 to 50 of about 2,524 (195)

Potential for Nirsevimab use in Pakistan

Journal of the Pakistan Medical Association
Respiratory Tract Infections can be classified as upper and lower tract infections. Upper tract infections are more common such as laryngitis and pharyngitis, but the infections of lower respiratory tract are more fatal such as influenza or bronchitis.
Muhammad Moaz, Basum Hayat
openaire   +3 more sources

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

Acta Paediatrica, Volume 115, Issue 11, Page 2380-2388, November 2026.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner, Despina D. Briana, Gian Carlo Di Renzo   +2 more
wiley   +1 more source

Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales [PDF]

, 2022
INTRODUCTION: Respiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease.
Koltai, Mihaly, Flasche, Stefan, Jit, Mark, Atkins, Katherine E; id_orcid, Hodgson, David, Krauer, Fabienne, Atkins, Katherine E   +6 more
core   +1 more source

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

, 2023
International audienceAbstract In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in ...
Amanda Leach, Wählby Hamrén, Ulrika, Mankad, Vaishali, Cabañas, Fernando, Fernando Cabañas, Domachowske, Joseph, Nguyen, Kim A, Kubiak, Robert J, Atanasova, Victoria, Victoria Atanasova, Furuno, Kenji, Robert J Kubiak, Ulrika Wählby Hamrén, Kubiak, Robert, Therese Takas, Leach, Amanda, Banu, Irfana, Nguyen, Kim An, Manish Shroff, Chang, Yue, Kenji Furuno, Kim A Nguyen, Shroff, Manish, Takas, Therese, Joseph B Domachowske, Vaishali S Mankad, Irfana Banu, Tonya Villafana, Yue Chang, Domachowske, Joseph B, Mankad, Vaishali S, Villafana, Tonya   +31 more
core   +1 more source

RSV Disease Among Hospitalized Children: Second vs. First Year of Life Multicenter Study

Influenza and Other Respiratory Viruses, Volume 20, Issue 11, November 2026.
ABSTRACT Background Respiratory syncytial virus (RSV) is a leading cause of pediatric hospitalization, yet data on children hospitalized with RSV in their second year of life are limited. Objective To compare clinical characteristics and management practices of children hospitalized with RSV during their second versus first year of life.
Keren Armoni Domany, Inbal Golan‐Tripto, Nitzan Burrack, Kamal Masarweh, Michal Gur, Mika Rochman, Moria Be'er, Dario Prais, Meirav Mor, Moran Weinberger Opek, Elias Nasrallah, Orli Megged, Rachel Shatzman Steuerman, Michal Stein, Zohar Steinberg, Shereen Shehadeh, Aharona Glatman‐Freedman, Diana Tasher   +17 more
wiley   +1 more source

Validation of Small‐Molecule Entry Inhibitors Targeting the Respiratory Syncytial Virus

ChemMedChem, Volume 21, Issue 20, 28 October 2026.
Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease, while effective treatments for acute infection are still limited. We screened small‐molecule RSV entry inhibitors and investigated promising hits through resynthesis and antiviral testing.
Christina Karhan, Svenja M. Sake, Melanie Urbanek‐Quaing, Diletta Bergamo, Jessica Rückert, Jiabin Huang, Christina Grethe, Antonia P. Gunesch, Anne Kühnel, Birthe Reinecke, Nicole Fischer, Thomas F. Schulz, Thomas Pietschmann, Anna K. H. Hirsch   +13 more
wiley   +1 more source

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations in the United States, with a significant seasonal impact on healthcare resources. Long-acting monoclonal antibodies (mAbs), nirsevimab and clesrovimab, provide
Benjamin Yarnoff, Matthieu Beuvelet, Samira Soudani, Maureen P. Neary, Erin N. Hodges, Ayman Chit, Maribel Tribaldos, Veronica Gabriel, Robert Musci, Jeroen Geurtsen, Leonard R. Krilov   +10 more
doaj   +1 more source

Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands

Human Vaccines & Immunotherapeutics
The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal ...
Annefleur C. Langedijk, Floris van den Dungen, Lisette Harteveld, Jennie van den Boer, Lucy Smit, Ahuva Averin, Erin Quinn, Mark Atwood, Amy Law, Diana Mendes, Marlies van Houten   +10 more
doaj   +1 more source

Pharmacokinetics, Immunogenicity, and Safety of a Modified YTE Antibody in Healthy Adults

Clinical Pharmacology in Drug Development, Volume 15, Issue 10, October 2026.
Abstract REGN17092, a fully human immunoglobulin (Ig) G1 antibody with M252Y/S254T/T256E (YTE) modification in the Fc portion, was assessed in a first‐in‐human study (ClinicalTrials.gov, NCT05923424). REGN17092 was designed to target the severe acute respiratory coronavirus 2 (SARS‐CoV‐2) S protein.
Maria Rosario, Jan de Hoon, Flonza Isa, Kenneth Turner, Jing Li, Joel Kantrowitz, Samit Ganguly, Sasha Fraser, Zhongqing Will He, Hong Yan, Ana Gonzalez Ortiz, Lori Faria, Ingeborg Heirman, Alina Baum, Thomas D Norton, Yogesh Patel, Veronica Mas Casullo, John D Davis   +17 more
wiley   +1 more source

Impact van nirsevimab op pediatrische RSV-infecties in België in 2024-2025. Een analyse van de routine sentinel-surveillancegegevens van Sciensano

We schatten dat 35 tot 45% van de ziekenhuisopnames is voorkomen door de introductie van nirsevimab. We schatten dat de introductie van nirsevimab heeft geleid tot 35-45% minder ziekenhuisopnames voor een RSV-infectie bij kinderen jonger dan 5 jaar.
T. Braeye, A. Lajot, L. Cornelissen, L. De Mot, S. Hanoteaux, Y. Dockx, B.E.L.S.A.R.I.N.E.Tresearch group, S. Denayer, Y. Lafort, I. Van Evercooren, M. Fonnesu, Y. Dupont, K. Blot, M. Vandromme, P. Mpakaniye, M.U. Paz   +15 more
core   +1 more source